Table 2.
Subgroup Analysis of the Pooled HRs of Overall Survival With TN-C Expression in Patients With Cancer.
| Subgroup Analysis | Studies (n) | Number of Patients | HR (95% CI) | Q Value | Heterogeneity | ||
|---|---|---|---|---|---|---|---|
| I 2 (%) | P | τ2 | |||||
| Sample type | |||||||
| Tissue | 14 | 2374 | 1.92 (1.33, 2.78) | 16.72 | 22.20 | .213 | 0.1085 |
| Serum | 3 | 292 | 0.77 (0.24, 2.41) | 3.47 | 42.40 | .176 | 0.4370 |
| Residence region | |||||||
| Asian | 11 | 1319 | 1.90 (1.15, 3.13) | 18.79 | 46.80 | .043 | 0.3273 |
| European | 7 | 1413 | 1.49 (1.06, 2.09) | 3.83 | 0.00 | .699 | 0.0000 |
| Clinicopathological features | |||||||
| LNM | 7 | 920 | 2.42 (1.79,3.26) | 9.27 | 35.30 | .159 | 0.0960 |
| DM | 4 | 489 | 1.72 (0.86,3.44) | 1.59 | 0.00 | .662 | 0.0000 |
| Sample size | |||||||
| <115 | 7 | 603 | 0.53 (0.28, 0.78) | 11.48 | 47.80 | .075 | 0.0000 |
| >115 | 11 | 2129 | 0.64 (0.44, 0.83) | 36.91 | 72.90 | .000 | 0.0000 |
Abbreviations: CI, confidence interval; DM, distant metastasis; HR, hazard ratios; LNM, lymph node metastasis; OS, overall survival; TN-C, tenascin-C.